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A B S T R A C T
Background: The association between chronic kidney disease (CKD) and functional status may change as a
function of the equation used to estimate glomerular filtration rate (eGFR). We reviewed the predictive value of
different eGFR equations in regard to frailty and disability outcomes.
Methods: We searched Pubmed from inception to March 2018 for studies investigating the association between
eGFR and self-reported and/or objective measures of frailty or disability. Cross-sectional and longitudinal studies
were separately analysed.
Results: We included 16 studies, one of which reporting both cross-sectional and longitudinal data. Three out of
7 cross-sectional studies compared different eGFR equations in regard to their association with functional status:
two studies showed that cystatin C-based, but not creatinine-based eGFR may be associated with hand-grip
strength or frailty; another study showed that two different creatinine-based eGFR equations may be similarly
associated with disability. Four out of 10 longitudinal studies provided comparative data: two studies reported
similar association with disability for different creatinine-based eGFR equations; one study showed that crea-
tinine-based eGFR was not associated with frailty, but a not significant trend for association was observed with
cystatin C-based eGFR; one study showed that cystatin C-based but not creatinine-based eGFR may predict
incident mobility disability, while both methods may predict gait speed decline. High heterogeneity was ob-
served in regard to confounders included in reviewed studies. None of them included the most recently published
equations.
Conclusion: Available data do not support the superiority of one of the eGFR equations in terms of measuring or
predicting functional decline.
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Progressive aging of the population in industrialized countries is
accompanied by an increase in the prevalence of chronic kidney disease
(CKD) [1]. Recently, it has been estimated that the residual lifetime
incidence of CKD among US people aged 65 or more is 42%, while the
prevalence of CKD among older adults is projected to increase from
13.2% currently to 14.4% in 2020 and 16.7% in 2030 [2]. Thus, CKD
has a relevant public health burden in the older population, resulting in
an increased risk of end-stage renal disease (ESRD), morbidity and
mortality [3].
Besides carrying negative prognostic implications in general and
selected diseased populations, including older ones [4–8], CKD also has
negative implications in terms of functional limitation and disability,
including impaired physical function [9, 10], frailty [11, 12], and sar-
copenia [13, 14]. Thus, early identification and management of CKD
patients are paramount for planning interventions aimed at slowing the
progression of kidney disease and associated comorbidities, but also to
delay the onset of its functional complications.
Currently available creatinine-based measures of kidney function
are plagued by some degree of inaccuracy and may provide discrepant
estimates [15, 16]. Indeed, several studies showed the existence of a U-
shaped relationship between creatinine-based eGFR and mortality in
frail and older people [17–20]. Additionally, creatinine-based eGFR
may systematically underestimate measured GFR at higher levels of
kidney function [21], leading to systematic over-diagnosis of CKD in
clinically healthy older people.
Efforts have been made to improve the estimating equations, espe-
cially in older patients. The Berlin Initiative Study (BIS) equations have
been developed and tested in older people and have been proved to be
accurate and precise in this population [22]. Nevertheless, the creati-
nine-based CKD-EPI (CKD-EPIcre) remains the recommended equation
also for older people [23], as the role and practical place of BIS equa-
tions have not been conclusively defined. Additionally, the potential
usefulness of cystatin C-based equations is still to be clarified. Finally,
given the mounting evidence about the disabling potential of CKD,
individual equations should be tested not only as for their accuracy in
predicting measured GFR as reference standard or traditional end-
points (e.g. mortality and end-stage renal disease (ESRD)), but also for
their ability in predicting functional outcomes.
Therefore, greater focus should be on the comparison between the
recommended CKD-EPIcre and other eGFR equations in predicting
functional status. Improving knowledge on this issue may assist in de-
signing CKD-related disability risk assessments and in tailoring inter-
ventions for older people. Thus, the purpose of this systematic literature
review was to (i) identify all studies reporting on the relationship be-
tween eGFR and self-reported or objectively measured functional status
among older people, and (ii) describe findings with regard to the dif-
ference between data obtained with CKD-EPIcre compared to other
eGFR equations.
2. Methods
2.1. Data Sources and Searching
We conducted a systematic literature review in MEDLINE (via
PubMed) from inception to March 2018, using the following syntax:
(Equation OR formula) AND (Berlin-Initiative-Study OR “CKD-EPI”
OR “CKDEPI” OR Chronic Kidney Disease Epidemiology Collaboration
OR Cockcroft-Gault OR MDRD4 OR (Modification of Diet in Renal
Disease) OR (Cystatin C) OR “Cystatin C"[Mesh] OR “Glomerular
Filtration Rate”[Mesh] OR Glomerular Filtration Rate OR BIS-1 OR
“CKD-EPI” OR BIS-2 OR “Kidney Function Tests”[Mesh] OR Schwartz
equation).
Only English language studies were selected for further evaluation.
A manual search of reference lists of relevant papers and reviews was
performed to identify additional articles.
2.2. Eligibility Criteria and Quality Assessment
Three assessors (MDR, PF, AC) independently screened title and
abstract of the records retrieved from the medical literature. The fol-
lowing eligibility criteria were used to retrieve studies to be included in
the review:
- Study design: Either cross-sectional or cohort (retrospective and
prospective) studies were included. All study settings and design
(cross sectional/longitudinal cohort) were included in further eva-
luation.
- Participants: studies not including people older than 65 years were
excluded, while studies including also people younger than 65 were
included for further evaluation.
- Reference assessment of eGFR: Creatinine-based CKD-EPI equation
was considered as the reference assessment of eGFR on the basis of
current recommendations [23].
- Comparators: We searched for studies comparing creatinine-based
CKD-EPI to other equations in regards to their association with
functional status. However, in order to obtain a comprehensive re-
view, we also included papers investigating only one eGFR equation.
- Outcomes: physical functional status outcomes were considered.
Studies including self-reported and/or objectively measured func-
tional status were gathered and analysed.
- Measures for cross-sectional studies: β coefficients for continuous
outcomes and ORs for binary outcomes. Measures for longitudinal
studies: HRs for survival analyses, β coefficients for continuous
outcomes and ORs for binary outcomes. Relative risk for eGFR
value< 60ml/min/1.73m2 was also extracted or calculated from
data reported in retrieved longitudinal studies.
The full-text of the articles selected by at least one of the assessors
was further evaluated. The same assessors extracted independently in-
formation from the selected studies, including study aims, population,
eGFR equation(s) used, specification of outcomes and main findings.
The list of confounders included in each study was also gathered.
Additional details were collected as deemed necessary. Any disagree-
ment was resolved through consensus building in the focus group. Data
were grouped according to study design (cross-sectional and cohort
studies).
Quality assessment was carried out by the same assessors using the
National Institutes of Health (NIH) Quality Assessment Tool for
Observational Cohort and Cross-Sectional Studies [24], a 14-item tool
designed to aid appraisal of internal validity (potential risk of selection,
information, or measurement bias, or confounding). Any disagreement
in quality assessment was resolved through consensus.
3. Results
Fig. 1 shows information about the process of literature review and
the reasons for inclusion and exclusion of identified citations. The
electronic search strategy identified a total number of 5796 citations. Of
these, 55 were considered as potentially eligible during title/abstract
evaluation and included in full-text assessment. Fourteen primary stu-
dies [9, 11, 12, 25–35] and one systematic review/meta-analysis [36]
were selected. The five studies included in the systematic review by
Shen et al. [36] were analysed: one study was excluded because it did
not include older people, while two other studies were excluded be-
cause kidney function was not estimated by eGFR. The remaining two
studies [37, 38] were retrieved, leading to a total of 16 studies included
in the analysis. One of the included studies reported both cross-sec-
tional and prospective data [38]. The overall number of subjects in-
cluded in reviewed studies was 45,381.
The equations used to calculate eGFR mentioned in this systematic
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review are reported in Table 1 [22, 39–44]. Study outcomes assessed in
retrieved studies are described in Table 2 [33, 45–51] [52].
3.1. Overview of Included cross-sectional studies
Among the 7 cross-sectional studies retrieved (Table 3), only three
studies provided a comparison between different eGFR equations in
regards to their association with functional status: Plantinga et al. [32]
compared CKD-EPIcre and MDRD, while Tufan et al. [33] compared
CKD-EPIcre, CKD-EPIcys and MDRD, and Dalrymple et al. [38] compared
CKD-EPIcre and CKD-EPIcys. Other cross-sectional studies used only
MDRD [29, 31], CKD-EPIcre [9], or CRIC [37] equations. Six studies
involved community-dwelling individuals [29, 31–33, 37], while only
one study included hospitalized patients [9]. The study by Plantinga
et al. [32] also included people aged 18–65 years, but only results for
subjects aged>65 were included in the present analysis. The outcomes
were self-reported in two out of six studies [29, 32], while one or more
objective measures of functional status were used in the remaining five
studies [9, 31, 33, 37, 38].
Among comparative studies, Plantinga et al. [32] showed that
MDRD-based stage 3-4 CKD is associated with higher prevalence of
disability into ability to work, type or amount of work performed,
walking or difficulties in basic activity of daily living (BADL), instru-
mental activities of living (IADL), leisure and social activities, lower
extremity mobility, and general physical activity. However, after ad-
justing for potential confounders most of these associations were no
longer significant, so that only disability in type or amount of work and
leisure-time activities resulted to be more prevalent in CKD compared
to no-CKD subjects. Similarly, a significantly increased adjusted pre-
valence of disability in leisure-time activities among patients with stage
3-4 CKD was observed when using CKD-EPIcre equation [32]. On the
other hand, Tufan et al. showed that CKD-EPIcys was significantly cor-
related to reduced hand grip strength, while MDRD and CKD-EPIcre
were not [33]. Finally, Dalrymple et al. [38] showed that CKD-
EPIcys < 45ml/min/1.73m2 was significantly associated with frailty,
while CKD-EPIcre was not.
Non comparative cross-sectional studies provided consistent results
across different outcome measures [9, 29, 31, 37]: MDRD was found
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Fig. 1. PRISMA diagram.
Table 1
Equations for estimating GFR used in reviewed studies.
CG [39] [(l40–age)×weight]/(72xScr) [×0.85 if female]





170 ∗ [Scr]− 0.999×age−0.176× BUN−0.170× serum
albumin0.318 [×0.762 in females] [×1.180 if black]
CKD-EPIcre
[41]
Female (Scr≤ 0.7) eGFR=144× (Scr/0.7)−0.329× (0.993)Age
(Scr > 0.7) eGFR=144× (Scr/0.7)−1.209× (0.993)Age
Male (Scr≤ 0.9) eGFR=141× (Scr/0.9)−0.411× (0.993)Age
(Scr > 0.9) eGFR=141× (Scr/0.9)−1.209× (0.993)Age
CKD-EPIcys
[42]
(Scys≤ 0.8), eGFR=133× (Scys/
0.8)−0.499 × 0.996Age[×0.932 if female]
(Scys > 0.8), eGFR=133× (Scys/
0.8)−1.328 × 0.996Age[×0.932 if female]
CRIC [44] Study equation is only available for CRIC study internal use
BIS1 [22] 3736× creatinine- 0.87× age- 0.95 [×0.82 if female]
BIS2 [22] 767× cystatin C–0.61× creatinine- 0.40× age- 0.57 [×0.87 if
female]
FAS [43] 107.3/(Scr/Q) for age= 2–40 years
[107.3/(Scr/Q)]× 0.998(Age-40) for age > 40 years
Q=mean or median Scr value for age−/sex-specific healthy
populations
Scr: serum creatinine; BUN: blood urea nitrogen; Scys: serum cystatin C; CG:
Cockcroft-Gault; MDRD: Modification of Diet in Renal Disease; CKD-EPI:
Chronic Kidney Disease Epidemiological Collaboration; CRIC, Chronic Renal
Insufficiency Cohort; BIS: Berlin Initiative Study; FAS: Full Age Spectrum.
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associated with 400-m walk time, lower extremity performance, grip
strength, knee extension [31]; eGFR decline≥25% (based on MDRD
equation) during the 10 years preceding functional assessment was
found associated with impaired SF36™ physical performance scale [29];
CKD-EPIcre was found associated with Short Physical Performance
Battery (SPPB) total score, balance and muscle strength sub-scores, but
not walking speed [9]; Chronic Renal Insufficiency Cohort (CRIC)
equation was found associated with SPPB total score and frailty [37]
(Table 3).
Overall, the quality of cross-sectional studies was fair (Table S1).
Sample size justification was reported by Lin et al. [29], while Lattanzio
et al. [9] and Plantinga et al. [32] reported different levels of kidney
function as related to the outcomes. Confounders included age, gender
and comorbidities (especially cardiovascular disease, diabetes, cancer,
and anemia) in the majority of studies [9, 29, 32, 37]. Results obtained
by Odden et al. [31] and Tufan et al. [33] were not adjusted for co-
morbidity, while the study by Lattanzio et al. [9] also included cogni-
tive status and cumulative comorbidity as potential confounders. Se-
lected studies also adjusted their analysis by serum albumin [9, 33].
3.2. Overview of included cohort studies
Among the 10 cohort studies (Table 4), only one study was retro-
spective, while the remaining nine had a prospective design. Pedone
et al. [12] provided a comparison between Cockcroft-Gault (CG) and
MDRD, while Bowling et al. [26] compared MDRD and CKD-EPIcre in
regard to their association with functional status. Dalrymple et al. [38]
and Liu et al. [30] compared the ability of CKD-EPIcys and CKD-EPIcre in
predicting incident frailty and mobility disability or change in gait
speed, respectively. Among the remaining cohort studies, two used
MDRD [11, 28], one used the 6-variables MDRD [25], and three used
CKD-EPIcre [27, 34, 35]. Seven out of ten studies involved community-
dwelling individuals [11, 12, 26–28, 30, 38], while the remaining three
were carried out in the hospital setting [25, 34, 35]. The outcomes were
self-reported in five studies [12, 26–28, 30] and objectively measured
or rated by study researchers in the remaining ones [11, 25, 34, 35, 38].
The comparative study by Pedone et al. [12] showed that both CG
and MDRD equations were able to predict the loss of at least 1 BADL
during a 6-years follow-up period among community-dwelling older
people. Bowling et al. [26] showed that both CKD-EPIcre and MDRD
were similarly associated with incident BADL and IADL dependency
during a 2-year follow-up. At variance, despite the observed increased
relative risk for CKD-EPIcre < 60ml/min/1.73m2, creatinine-based
eGFR did not predict incident frailty after adjusting for potential con-
founders in the study by Dalrymple et al., while a not significant trend
for increased risk was observed with CKD-EPIcys [38]. Finally, Liu et al.
showed that CKD-EPIcys but not CKD-EPIcre may predict incident mo-
bility disability, while both equations may predict gait speed decline
[30].
Non comparative studies showed that MDRD equation could predict
IADL and BADL decline, as well as difficulty in walking or climbing
stairs [11, 28]. The 6-variable MDRD equation could predict motor, but
not total Functional Impairment Measurement (FIM) score at discharge
among older patients with hip fracture in the only study with retro-
spective design [25]. CKD-EPIcre was found associated with IADL and
BADL decline, self-reported difficulty in walking or climbing stairs, and
gait speed decline in community-dwelling individuals [27, 30]. The
relative risk for incident stroke disability was also increased among
hospitalized patients with CKD-EPIcre eGFR<60ml/min/1.73 m2, but
such an association was no longer significant in multivariable analysis
[34, 35] (Table 4).
None of the cohort studies reported sample size justification. The
exposure variable was assessed more than once over time only in the
studies by Adunsky et al. [25] and Dalrymple et al. [38]. Relative risk or
data for its calculation were available for eight out of ten cohort studies
reviewed. Subjects lost to follow up were not reported in five out of
eight studies [12, 25, 30, 34, 35] (Table S1). Age, gender, cardiovas-
cular comorbidities and diabetes were the most frequently included
Table 2
Summary of outcomes reported in reviewed studies.
Outcome(s) Description
Self-reported
Working, walking and cognition Self-reported limitation in listed tasks
Leisure and social activities Self-reported limitation in listed tasks
Lower extremity mobility Self-reported limitation in listed tasks
General physical activity Self-reported limitation in listed tasks
Walking or climbing stairs Self-reported limitation in listed tasks
Basic activities of daily living (BADL) [49] Rating dependency in bathing, dressing, toileting, transferring, continence, eating
Instrumental activities of daily living (IADL) [50] Rating dependency in ability to use telephone, shopping, food preparation, housekeeping, laundry, mode of transportation,
managing medications, managing money
Short Form-36 (SF36) physical function scale
(PFS) [51]
SF36 is a 36-item questionnaire which measures Quality of Life across eight domains, including: physical functioning; role
limitations due to physical health; role limitations due to emotional problems; energy/fatigue; emotional well-being; social
functioning; pain; general health. The Physical function scale is calculated as average score of items 3 to 12.
Functional Independence Measurement (FIM) [52] The FIM is an 18-item, 7-level functional assessment designed to evaluate the amount of assistance required by a person with
a disability to perform basic life activities safely and effectively.
Objectively measured or mixed
400-m walk time Time taken to walk a distance of 400m
Lower extremity performance score [45, 46] Modified version of the lower extremity performance test used in the Established Populations for Epidemiologic Studies of
the Elderly (EPESE), including five repeated chair stands, semi-tandem, full tandem, and single-leg standing balance tests, a
6-min walking test to determine usual gait speed, and a narrow walk test of balance.
Hand grip strength Isokinetic dynamometer
Sarcopenic hand grip strength (HGS) [33] Hand grip strength< 29 kg when BMI < 24 kg/m2,< 30 kg when BMI=24.1–28 kg/m2,< 32 kg when BMI > 28 kg/m2
Knee extension strength Isokinetic dynamometer
Walking (gait) speed Gait speed in m/s measured on a 4-or 6-m path at usual pace.
SPPB [45] The short physical performance battery (SPPB) is a group of measures that combines the results of walking speed, chair stand
and balance tests.
Frailty [47] Frailty if defined as a clinical syndrome in which three or more of the following criteria are present: unintentional weight
loss, weakness (handgrip strength), self-reported exhaustion or poor endurance, slowness (walking speed), and low physical
activity (kilocalories expended per week).
Rankin scale [48] Measures the degree of disability or dependence in the daily activities of people with stroke or other neurological
disabilities. The 6 levels of rating are: no symptoms; no significant disability despite symptoms; slight disability; moderate
disability; moderately severe disability; severe disability; dead.
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Table 3
Summary of findings from retrieved cross-sectional studies.
Study N Age Design and
setting
Outcome(s) eGFR method Main results
Odden [31] 3043 74 Cross-sectional 400-m walk time MDRD Among patients with eGFR<60ml/min/1.73 m2
- 400-m walking time: β=19.7, 95%CI= 9.2–30.1
- Lower extremity performance: β=−0.18,
95%CI=−0.26- -0.10
- Grip strength: β=−1.9, 95%CI=−3.0- -0.7
- Knee extension: β=−10.2, 95%CI=−14.7- -5.6
Among patients with eGFR≥60ml/min/1.73m2
- 400-m walking time: β=−3.5, 95%CI=−7.0–0.0
- Lower extremity performance: β=0.04,
95%CI= 0.02–0.07
- Grip strength: β=0.9, 95%CI= 0.5–1.3
- Knee extension: β=3.8, 95%CI=2.2–5.5
Lower extremity performance scoreCommunity-
dwelling Grip strength
Knee extension strength
Lin [29] 2544 67 Cross-sectional SF36 physical function scale (PFS) MDRD Association between former eGFR decline ≥25% and actual
PFS
- Linear analysis: β=−3.5, 95%CI=−5.4, −1.5
- Logistic regression analysis considering PFS≤ 65 as
outcome variable: OR=1.37, 95%CI= 1.04–1.81 (not




Plantinga [32] 16,011 ≥65 Cross-sectional Self-reported limitations in:
• Working, walking, and cognition;• BADL;• IADL;• Leisure and social activities;• Lower extremity mobility;• General physical activity
MDRD Stage 3–4 CKD compared to no CKD Using MDRD:
- Adjusted prevalence of disability in type or amount of
work performed (43.7 (95%CI= 39.0–48.4) vs 39.0
(95%CI= 35.5–42.4), p < .05)
- Adjusted prevalence of disability in leisure time activities
(21.5 (95%CI= 18.5–24.6) vs 17.4 (95%CI= 15.5–19.3),
p < .05)
Using CKD-EPIcre:
- Adjusted prevalence of disability in leisure time activities





Lattanzio [9] 486 80.1 Cross-sectional SPPB, either global score or its individual
components (muscle strength, balance, and
walking speed)
CKD-EPIcre Linear association between eGFR and:
- SPPB total score (B= 0.49, 95%CI= 0.18–0.66)
- Balance (B= 0.30, 95%CI= 0.10–0.49)
- Muscle strength (B=0.06, 95%CI= 0.01–0.10)
- Walking speed (B=−0.04, 95%CI=−0.09–0.11)
Compared to patients with eGFR>60:
- eGFR=30.0–44.9, adjusted mean difference− 1.28
(95%CI=−2.37- -0.18) for SPPB total score, and− 0.63
(95%CI=−1.12- -0.14) for balance score;
- eGFR<30, adjusted mean difference− 2.26
(95%CI=−3.60- -0.93) for total SPPB score, −0.76
(95%CI=−1.30- -0.22) for muscle strength score,
and− 1.03 (95%CI=−1.63 to −0.43).
Hospital
Dalrymple [38] 4150 ≥65 Cross-sectional Frailty (slow gait speed, muscle weakness, low
physical activity, exhaustion and
unintentional weight loss)
CKD-EPIcre CKD-EPIcre≥ 90: reference
- 76–89 OR=0.48 (95%CI 0.42–0.73)
- 60–75 OR=0.59 (95%CI 0.39–0.89)
- 45–59 OR=0.69 (95%CI 0.45–1.07)
- 15–44 OR=0.83 (95%CI 0.49–1.41)
CKD-EPIcys≥ 90: reference
- 76–89 OR=0.77 (95%CI 0.48–1.31)
- 60–75 OR=1.05 (95%CI 0.64–1.72)
- 45–59 OR=1.47 (95%CI 0.89–2.43)




Reese [37] 1111 65.0 Cross-sectional SPPB; Frailty (slow gait speed, muscle
weakness, low physical activity, exhaustion
and unintentional weight loss)
CRIC For SPPB
- eGFR 30–59: β=−0.51, 95%CI=−0.80 - -0.22;
- eGFR 15–29: β=−0.61, 95%CI=−1.03 - -0.19;
- eGFR<15: β=−1.75, 95%CI=−2.33 - -1.16.
For frailty
- eGFR 30–59: OR=1.45, 95%CI= 1.05–1.99;
- eGFR 15–29: OR=2.02, 95%CI= 1.29–3.16;
- eGFR<15: OR=4.83, 95%CI=2.60–8.98.
Community-
dwelling
(continued on next page)
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confounders in cohort studies [11, 12, 28, 30, 34, 35, 38]. Other po-
tential confounders considered in cohort studies were serum albumin
[25, 27, 28, 38], hemoglobin [25, 27, 28, 38], lipids [27, 38], smoking
habits and alcohol consumption [27, 30, 34, 35]. Few studies also in-
cluded cognitive status [25, 26, 28], depression [28] and physical ac-
tivity [28, 30] among potential confounders.
4. Discussion
Our systematic review shows that eGFR is associated with different
phenotypes of functional impairment in most of the studies included in
the analysis. However, selected differences among studies deserve
mention. Indeed, two comparative cross-sectional studies showed that
CKD-EPIcys, but not MDRD and/or CKD-EPIcre was associated with hand
grip strength or frailty [33, 38]. Additionally, one comparative cohort
study showed CKD-EPIcre may not predict incident frailty, while a not
significant trend for increased risk could be observed with CKD-EPIcys
[38]. Finally, CKD-EPIcre was not associated with incident stroke dis-
ability [34, 35]. Thus there is consistent uncertainty, if changes in
kidney function estimated with different equations may predict phe-
notypes of functional decline with different accuracy.
While the potential superiority of cystatin C-based equations in
predicting functional status needs to be further investigated in com-
parative studies, the small evidence currently available suggests that
sarcopenia may represent an important confounder in the association
between eGFR and functional phenotypes. Indeed, normal or even high
eGFR based on a calculation using serum creatinine may at least partly
reflect inflammation, frailty and/or muscle loss with consequent re-
duced creatinine production rather than normal kidney function [53,
54]. This incongruence affirms the need for new approaches to estimate
kidney function in elderly individuals. Ideally, a new formula should
not only extrapolate age-associated declining muscle mass but also re-
flect functional decline.
eGFR has been considered a key prognostic and classificatory in-
dicator in public health campaigns, whereas serum creatinine is an
unreliable marker of renal function [55]. Equations have been devel-
oped by incorporating demographic and clinical variables as surrogates
for unmeasured physiological factors, such as creatine generation and
tubular secretion, that contribute – apart from filtration function – to
serum creatinine concentration [22, 40–42]. Estimating equations
seems to be reasonably accurate in detecting changes in kidney function
over time [56]. However, the distinctive lack of data comparing the
predictive value of different eGFR equation in regard to functional
status observed in the present study is a relevant issue because the
accuracy in predicting outcomes may change as a function of the
equation used. Indeed, disagreement between eGFR equations has been
consistently reported [15, 16, 57–60], with age, gender, weight, and
study setting representing important sources of discrepancy between
equations [15]. Thus, results obtained with different equations may be
difficult to interpret. As an example, a U-shaped relationship between
eGFR and mortality has been observed by using MDRD [17], CKD-EPIcre
[18, 20], and BIScre [61], but not with cystatin-C-based CKD-EPI
equation [20]. This evidence further suggests that eGFR may not only
reflect kidney function, but rather muscle loss, which may contribute to
a low serum creatinine concentration [61]. Such hypothesis is also
sustained by the observation that both low serum creatinine and low
24 h urine creatinine are associated with adverse outcomes [62], while
cystatin C is less influenced by body composition [63]. Nevertheless,
only two longitudinal study [30, 38] and two cross-sectional studies
[33, 38] compared the predictive value of creatinine- and cystatin C-
based eGFR in regard to functional status.
Current evidence suggests that filtration markers other than serum
creatinine and not affected by muscle loss (i.e. cystatin C, beta-trace
protein and beta2-microglobulin) [64] may better predict negative
outcomes, but their usefulness in predicting functional decline is still to
be investigated. Despite CKD-EPIcre remains recommended as a re-
ference equation [23], it may not perform better than other equations
in predicting outcomes in older populations [58, 65]. The cross-sec-
tional association between MDRD or CKD-EPIcre and disabilities was no
longer significant after adjusting for potential confounders [32]. On the
other hand, CKD-EPIcys, but not CKD-EPIcre was found cross-sectionally
associated with frailty [38]. In cohort studies, CG, MDRD and CKD-
EPIcre showed similar associations with incident disability [12, 26].
However, when comparing CKD-EPIcre and CKD-EPIcys in regard to their
ability to predict incident frailty or mobility disability, only the latter
equation showed a near significant trend for increased risk [30, 38].
Thus, available studies are not sufficient to build a meta-analysis of
comparative studies. Additionally, it is worth noting that we could not
find any study including the most recent equations addressing the issue
of estimating kidney function among older people. The BIS equations
have been specifically developed in an older population and published
in 2012 [22]. It showed a reduced rate of misclassification of CKD
stages [22, 56], which was confirmed in two external validation studies
in older patients [66, 67]. In our review, three cross-sectional studies
and five longitudinal studies were published after 2012, but none of
them included BIS equation for kidney function assessment. Further-
more, the Full Age Spectrum (FAS) equation has been published in
2016, and it has been mathematically obtained by requiring continuity
during the pediatric–adult and adult–old age transition to improve
validity across the full age spectrum [68]. Thus, it seems sensible to
suggest for including BIS and FAS equations in future studies in-
vestigating the relationship between kidney function and functional
impairment.
The major strengths of the present study are the careful study se-
lection and the assessment of their quality, both of which contribute to
provide a reliable overview of the evidence in this research field.
Additionally, most of the retrieved studies involve community-dwelling
older people, which likely enhance the generalizability of our results.
As for limitations, more than one-third of reviewed studies are cross-
sectional, which limits the exploration of the causal relationship be-
tween eGFR and functional status. Another important limitation is the
frequent use of self-reported outcome measures. Indeed, the outcome
was self-reported in two out of seven cross-sectional studies, and in five
out of ten cohort studies. Finally, a high heterogeneity was observed in
confounding variables included in retrieved studies. Future studies are
expected to bridge these gaps by using both objective and subjective
outcome measures in order to increase the strength of evidence. From
this point of view, the Screening for Chronic Kidney Disease among
Older People across Europe (SCOPE) project, a large prospective mul-
ticenter cohort study, represents an important ongoing effort towards
Table 3 (continued)
Study N Age Design and
setting
Outcome(s) eGFR method Main results
Tufan [33] 209 67.8 Cross-sectional Hand grip strength (HGS). MDRD Only CKDEPIcys < 60 was significantly associated with
sarcopenic HGS (OR=2.40, 95%CI= 1.04–5.40).CKDEPIcreCommunity-
dwelling
Sarcopenic HGS was defined as (< 29 kg
when BMI < 24 kg/m2,< 30 when
BMI=24.1–28 kg/m2, and < 32 kg when
BMI > 28 kg/m2)
CKDEPIcys
MDRD, Modification of Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiological Collaboration; CRIC, Chronic Renal Insufficiency Cohort.
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Table 4
Summary of findings from retrieved cohort studies.
Study N Age Design and setting Outcome(s) eGFR
method
Main results
Fried [11] 2135 73.5 Prospective Difficulty in walking 1/4 mile or
climbing 10 steps on two consecutive
reports 6months apart.
MDRD Relative risk not available
F.U.: Up to 54months eGFR<60: HR=1.30 (95%CI=1.08–1.56)
Community-dwelling
Bowling [26] 357 77.4 Prospective IADL decline MDRD Using MDRD equation -
- Relative risk for eGFR<60 was 2.05, 95%CI= 1.80–2.30
for IADL decline and 2.89, 95%CI= 2.63–3.15 for BADL
decline.
- eGFR<60: OR=1.83 (95%CI= 1.06–3.17) for IADL
decline; OR=2.46 (95%CI= 1.19–5.12) for BADL decline.
- eGFR<45: OR=3.12 (95%CI= 1.38–7.06) for IADL
decline; OR=3.78 (95%CI= 1.36–9.77) for BADL decline.
Using CKD-EPIcre equation –
- Relative risk for eGFR<60 was 2.49, 95%CI= 2.30–2.68
for IADL decline and 2.42, 95%CI= 2.19–2.64 for BADL
decline.
- eGFR<60 was significantly associated with IADL decline
(unadjusted OR=3.40, 95% CI=2.00–5.77) and BADL
decline (unadjusted OR=2.56; 95% CI= 1.29–5.08). These
associations were similar after multivariable adjustment
(data not shown).
BADL decline CKD-EPIcreF.U.: 2 yrs.
Community-dwelling




Relative risk not available
eGFR was significantly associated with motor FIM (β=0.028,
p= .022) but not total FIM (β=0.072, p= .101).
Hospital
Hip fracture patients
Feng [28] 1186 65.6 Prospective IADL decline (total and cognitive) MDRD eGFR<60:
IADL decline -
- Relative risk for eGFR<60=2.91, 95%CI= 2.60–3.22
- OR=1.99, 95%CI= 1.16–3.41
IADL cognitive decline -
- Relative risk not available
- OR=2.06, 95%CI= 1.07–3.94 for cognitive IADL decline
F.U.: 4 yrs.
Community- dwelling
Pedone [12] 666 73.1 Prospective Loss of independency in ≥1 BADL CG eGFR<60:
- Relative risk for CG < 60=1.90 (95%CI= 1.11–3.26)
- HR=4.40 (95%CI= 2.80–6.94) for CG
- Relative risk for MDRD<60=1.72 (95%CI= 1.09–2.70)
- HR=3.19 (95%CI= 2.12–4.79) for MDRD
F.U: 6 yrs. MDRD
Community-dwelling
Dalrymple [38] 4150 ≥65 Prospective Frailty (slow gait speed, muscle
weakness, low physical activity,
exhaustion and unintentional weight
loss)
CKD-EPIcre CKD-EPIcre≥ 90: reference
- Relative risk for eGFRcre < 60=1.30, 95%CI= 1.07–1.53
- 76–89 IRR=0.60 (95%CI 0.37–0.97)
- 60–75 IRR=0.86 (95%CI 0.54–1.37)
- 45–59 IRR=0.67 (95%CI 0.40–1.12)
- 15–44 IRR=1.08 (95%CI 0.58–2.01)
CKD-EPIcys≥ 90: reference
- Relative risk for eGFRcys < 60=1.55, 95%CI= 1.39–1.71
- 76–89 IRR=1.51 (95%CI 0.80–2.86)
- 60–75 IRR=1.62 (95%CI 0.88–2.99)
- 45–59 IRR=1.77 (95%CI 0.89–3.13)
- 15–44 IRR=1.87 (95%CI 0.95–3.69)
Community-dwelling CKD-EPIcys
Chin [27] 984 ≥65 Prospective IADL decline CKD-EPIcre eGFR≥ 60: reference
For IADL decline –
- Relative risk for eGFR<60=2.36, 95%CI= 1.63–3.09
- eGFR 45–59: OR=1.41, 95%CI= 0.82–2.44
- eGFR<45: OR=3.0, 95%CI= 1.57–5.74
For BADL decline -
- Relative risk for eGFR<60=2.24, 95%CI= 1.81–2.67
- eGFR 45–59: OR=0.64, 95%CI= 0.20–2.00
- eGFR<45: OR=2.94, 95%CI= 0.99–8.73
F.U.: 59.4 ± 6.9 months BADL decline
Community-dwelling
(continued on next page)
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achieving this goal (ClinicalTrial.govNCT02691546).
5. Conclusions
Low eGFR is significantly associated with impaired functional status
among older people. However, our findings do not allow to draw a
definitive conclusion on which eGFR equation may better predict self-
reported and/or objectively measured functional decline. Further stu-
dies based on longitudinal design and including both self-reported and
objective outcome measures, as well as eGFR assessment by equations
specifically developed in older people, and cystatin-based ones may be
very informative and helpful to define CKD-related disability risk as-
sessment among older people.
Acknowledgments
The Authors are grateful to Drs Antonio Cherubini, Iosief Abraha




All Authors declare to have no competing interests with this
manuscript.
Funding
The work reported in this publication was granted by the European
Union Horizon 2020 program (Grant Agreement no 634869). Funder
had no role in the systematic review.
Authors' contributions
Andrea Corsonello, Regina Roller-Wirnsberger and Fabrizia
Lattanzio conceived the study and participated in manuscript writing
and revising.
Andrea Corsonello, Mirko Di Rosa and Paolo Fabbietti carried out
literature search.
Gerhard Wirnsberger, Tomasz Kostka, Agnieszka Guligowska,
Francesco Mattace-Raso, Lisanne Tap, Pedro Gil, Lara Guardado
Fuentes, Itshak Meltzer, Ilan Yehoshua, Francesc Formiga-Perez, Rafael
Moreno-González, Christian Weingart, Ellen Freiberger, Johan Ärnlöv
and Axel C. Carlsson participated in manuscript revision and approval.
Appendix A. SCOPE study Investigators
A.1. Coordinating Center
Fabrizia Lattanzio, Italian National Research Center on Aging
(INRCA), Ancona, Italy – Principal Investigator.
Andrea Corsonello, Silvia Bustacchini, Silvia Bolognini, Paola
D'Ascoli, Raffaella Moresi, Giuseppina Di Stefano, Laura Cassetta, Anna
Rita Bonfigli, Roberta Galeazzi, Federica Lenci, Stefano Della Bella,
Enrico Bordoni, Mauro Provinciali, Robertina Giacconi, Cinzia Giuli,
Demetrio Postacchini, Sabrina Garasto, Annalisa Cozza - Italian
National Research Center on Aging (INRCA), Ancona, Fermo and
Cosenza, Italy – Coordinating staff.
Romano Firmani, Moreno Nacciariti, Mirko Di Rosa, Paolo Fabbietti
– Technical and statistical support.
A.2. Participating Centers
- Department of Internal Medicine, Medical University of Graz,
Austria: Gerhard Hubert Wirnsberger, Regina Elisabeth Roller-
Wirnsberger.
Table 4 (continued)
Study N Age Design and setting Outcome(s) eGFR
method
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Liu [30] 1226 68.0 Prospective Self-reported inability to walk 1/2
mile and/or climb a flight of stairs
CKD-EPIcre eGFRcre < 60:
F.U.: 6.6 yrs. For mobility disability
- Relative risk for eGFR<60=1.26, 95%CI= 0.86–1.67
- OR=1.03, 95%CI= 0.64–1.62
For gait speed decline -
- Relative risk not available
- β=0.07, SE= 0.03, p= .0004
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- OR=1.55, 95%CI= 1.05–2.31
For gait speed decline
- Relative risk not available
- β=0.07, SE= 0.02, p= .0022
Community-dwelling CKD-EPIcysGait speed decline
Wang [34] 8865 69.5 Prospective Stroke disability (Rankin scale) CKD-EPIcre eGFR≥ 90: reference
- Relative risk for eGFR<60=1.49, 95%CI= 1.37–1.61
- eGFR<45: OR=1.26, 95%CI= 0.95–1.67
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- eGFR 45–59: OR=1.09, 95%CI= 0.75–1.59
- eGFR 60–89: OR=0.87, 95%CI= 0.67–1.14
F.U.: 90 days
Hospital (stroke registry)
F.U., follow-up; MDRD, Modification of Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiological Collaboration; CG, Cockcroft-Gault.
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